LeadIQ logo
Learn more at LeadIQ.com

Insights

Loading spinner
Gathering insights about Seres Therapeutics

Similar companies to Seres Therapeutics

Seres Therapeutics Tech Stack

Seres Therapeutics uses 8 technology products and services including Drupal, TrackWise Digital, Font Awesome, and more. Explore Seres Therapeutics's tech stack below.

  • Drupal
    Content Management System
  • TrackWise Digital
    Data Quality Management
  • Font Awesome
    Font Scripts
  • Smartsheet
    Project Management
  • MLS
    Realty
  • Microsoft Teams
    Team Collaboration
  • Minitab
    Visualisation Software
  • Flask
    Web Frameworks

Media & News

Seres Therapeutics's Email Address Formats

Seres Therapeutics uses at least 1 format(s):
Seres Therapeutics Email FormatsExamplePercentage
FLast@serestherapeutics.comJDoe@serestherapeutics.com
97%
FirstLast@serestherapeutics.comJohnDoe@serestherapeutics.com
1%
LastFirst@serestherapeutics.comDoeJohn@serestherapeutics.com
1%
FMiddleLast@serestherapeutics.comJMichaelDoe@serestherapeutics.com
1%

Frequently Asked Questions

Where is Seres Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Seres Therapeutics's main headquarters is located at 101 Cambridgepark Dr Cambridge, Massachusetts 02140 US. The company has employees across 5 continents, including North AmericaEuropeSouth America.

What is Seres Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Seres Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Seres Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Seres Therapeutics is a publicly traded company; the company's stock symbol is MCRB.

What is Seres Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Seres Therapeutics's official website is serestherapeutics.com and has social profiles on LinkedIn.

How much revenue does Seres Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2024, Seres Therapeutics's annual revenue reached $75M.

What is Seres Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Seres Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Seres Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2024, Seres Therapeutics has approximately 275 employees across 5 continents, including North AmericaEuropeSouth America. Key team members include Chief Technology Officer & Evp Process Development, Quality & Supply: D. E.Chief Medical Officer: L. V. M.Vice President Corporate Strategy: W. D.. Explore Seres Therapeutics's employee directory with LeadIQ.

What industry does Seres Therapeutics belong to?

Minus sign iconPlus sign icon
Seres Therapeutics operates in the Biotechnology Research industry.

What technology does Seres Therapeutics use?

Minus sign iconPlus sign icon
Seres Therapeutics's tech stack includes DrupalTrackWise DigitalFont AwesomeSmartsheetMLSMicrosoft TeamsMinitabFlask.

What is Seres Therapeutics's email format?

Minus sign iconPlus sign icon
Seres Therapeutics's email format typically follows the pattern of . Find more Seres Therapeutics email formats with LeadIQ.

How much funding has Seres Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2024, Seres Therapeutics has raised $110M in funding. The last funding round occurred on Apr 27, 2023 for $110M.

When was Seres Therapeutics founded?

Minus sign iconPlus sign icon
Seres Therapeutics was founded in 2010.
Seres Therapeutics

Seres Therapeutics

Biotechnology ResearchMassachusetts, United States201-500 Employees

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.

For more information, please visit http://www.serestherapeutics.com/ .

Section iconCompany Overview

Headquarters
101 Cambridgepark Dr Cambridge, Massachusetts 02140 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MCRB
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
201-500

Section iconFunding & Financials

  • $110M

    Seres Therapeutics has raised a total of $110M of funding over 10 rounds. Their latest funding round was raised on Apr 27, 2023 in the amount of $110M.

  • $50M$100M

    Seres Therapeutics's revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $110M

    Seres Therapeutics has raised a total of $110M of funding over 10 rounds. Their latest funding round was raised on Apr 27, 2023 in the amount of $110M.

  • $50M$100M

    Seres Therapeutics's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.